Anika Therapeutics, Inc. (ANIK) P/E ratio
The P/E ratio of Anika Therapeutics, Inc. (ANIK) was 128.0× at the end of fiscal 2021 (December 31, 2021). Figures as of 18 Nov 2026, 12:38 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio, fiscal 2021
- 128.0×
- Highest on record
- 128.0×fiscal 2021
- Lowest on record
- 12.1×fiscal 2012
- Fiscal years on record
- 122009–2021
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Anika Therapeutics, Inc. P/E ratio, in more detail
Across the 12 fiscal year-ends on record (2009–2021), the highest was 128.0× in fiscal 2021 and the lowest 12.1× in fiscal 2012.
P/E ratio at each fiscal year-end
Anika Therapeutics, Inc. P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | $9.61 | -$0.76 | |
| 2024 | — | — | $16.46 | -$3.83 | |
| 2023 | — | — | $22.66 | -$5.64 | |
| 2022 | — | — | $29.60 | -$1.02 | |
| 2021 | 128.0× | — | $35.83 | $0.28 | |
| 2020 | — | — | $45.26 | -$1.69 | |
| 2019 | 27.4× | 3.7% up | $51.85 | $1.89 | |
| 2018 | 26.5× | 3.6% up | $33.61 | $1.27 | |
| 2017 | 25.5× | 12.2% up | $53.91 | $2.11 | |
| 2016 | 22.8× | 19.9% up | $48.96 | $2.15 | |
| 2015 | 19.0× | 17.0% up | $38.16 | $2.01 | |
| 2014 | 16.2× | 40.9% down | $40.74 | $2.51 | |
| 2013 | 27.5× | 126.5% up | $38.16 | $1.39 | |
| 2012 | 12.1× | 23.3% down | $9.94 | $0.82 | |
| 2011 | 15.8× | 24.2% down | $9.80 | $0.62 | |
| 2010 | 20.8× | 12.6% down | $6.67 | $0.32 | |
| 2009 | 23.8× | — | $7.63 | $0.32 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
Anika Therapeutics, Inc., figure by figure
- Anika Therapeutics, Inc. market cap
- Anika Therapeutics, Inc. revenue
- Anika Therapeutics, Inc. earnings
- Anika Therapeutics, Inc. earnings per share (EPS)
- Anika Therapeutics, Inc. P/S ratio
- Anika Therapeutics, Inc. P/B ratio
- Anika Therapeutics, Inc. free cash flow
- Anika Therapeutics, Inc. operating margin
- Anika Therapeutics, Inc. dividend
- Anika Therapeutics, Inc. shares outstanding
- Anika Therapeutics, Inc. total debt
- Anika Therapeutics, Inc. cash on hand
- Anika Therapeutics, Inc. total assets
- Anika Therapeutics, Inc. return on equity (ROE)
- Anika Therapeutics, Inc. return on invested capital (ROIC)
Anika Therapeutics, Inc. (ANIK) overview: price, valuation and scorecard
Anika Therapeutics, Inc. P/E ratio: questions and answers
What is Anika Therapeutics, Inc.'s P/E ratio?
The P/E ratio of Anika Therapeutics, Inc. (ANIK) was 128.0× at the end of fiscal 2021 (December 31, 2021).
What are the highest and lowest P/E ratio figures on record for Anika Therapeutics, Inc.?
Across the 12 fiscal year-ends on record (2009–2021), the highest was 128.0× in fiscal 2021 and the lowest 12.1× in fiscal 2012.
How is Anika Therapeutics, Inc.'s P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Anika Therapeutics, Inc. it is on record here for 12 fiscal years, 2009 to 2021.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Anika Therapeutics, Inc. (ANIK) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ANIK/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.